Meet CB Therapeutics co-founders Sher Butt and Jacob Vogan, PhD, and the Carlsbad team working across synthetic biology, precision fermentation, alkaloid biosynthesis, and AI-guided biological design.
CB Therapeutics expands its precision-fermentation platform to produce ergoline compounds for neurological and psychiatric research. The announcement describes the work as sustainable ergoline biosynthesis.
CB Therapeutics introduces a precision-fermentation process for manufacturing retinol for the skincare market, presenting it as a sustainable production approach.
CB Therapeutics announces it is producing pharmaceutical-grade cannabinoids and analogues through precision fermentation. The compounds are intended for drug developers.
CB Therapeutics uses yeast-based precision fermentation to produce psilocybin, psilocin, and DMT for psychedelic research. SynBioBeta profiles this approach to enabling research.
